Rabies is one of the neglected tropical diseases, almost 100% fatal, but preventable. Rabies virus causes the disease and causes about 59000 human deaths annually. The author searched the Pubmed Database at NCBI for articles on rabies disease published between 2007 and 2018. All articles are open access, free for redistribution and in English. To examine rabies virus, Seller’s test was used. In this article, references written by the author were included and relevant publications were also included. The author reviewed a rabies dog case kept at Nelwan Institution for Human Resource Development. The dog showed clinical signs such as aggressive behavior, in-appetence, and soaking in water. Currently, there are no drugs to treat rabies. Vaccination is the best way to prevent the disease. To eradicate rabies, mass vaccination in dogs, post-exposure prophylaxis, and gene therapy can be used. To prevent rabies disease, minimum 70% of the dog population should receive vaccination. Humans with category II exposure should receive rabies vaccine and rabies immunoglobulin. For treatment, in vivo experiment showed that gene therapy can eliminate rabies from the infected neurons by using rAAV-N796. To fight rabies virus, induced pluripotent cells in combination with CRISPR/Cas9 system can also be beneficial. Furthermore, it needs US$ 8.6 billion to fight rabies annually.

Rabies remains a global health threat despite being preventable with post-exposure prophylaxis (PEP). This study assessed one-year humoral and T cell immunity in PEP recipients of the Insitut Pasteur du Cambodge (IPC) regimen, recommended by WHO. We analyzed rabies virus (RABV) neutralizing antibodies (nAbs) and T cell responses at baseline, 7 and 14 days, 6 and 12 months after PEP. A total of 148 patients were included, with 78 bitten by confirmed RABV-positive dogs receiving PEP and equine rabies immunoglobulins (eRIG), and 70 bitten by RABV-negative dogs receiving only PEP. Fourteen days after PEP, all but two individuals seroconverted for nAbs ( ≥ 0.5 IU/mL) with 87% maintaining this response even after 12 months. Interleukin-4 (IL-4) and interferon-gamma (IFN-γ)-secreting T cells were significantly elevated after 14 days and sustained for one year. No differences were observed between the RABV-exposed and -unexposed groups. This study demonstrates robust one-year immunity after IPC PEP.

Tracking lethal threat: In-depth review of rabies An infectious disease known as rabies (family Rhabdoviridae, genus Lyssavirus) causes severe damage to mammals' central nervous systems (CNS). This illness has been around for a very long time. The majority of human cases of rabies take place in underdeveloped regions of Africa and Asia. Following viral transmission, the Rhabdovirus enters the peripheral nervous system and proceeds to the CNS, where it targets the encephalon and produces encephalomyelitis. Postbite prophylaxis requires laboratory confirmation of rabies in both people and animals. All warm-blooded animals can transmit the Lyssavirus infection, while the virus can also develop in the cells of cold-blooded animals. In the 21st century, more than 3 billion people are in danger of contracting the rabies virus in more than 100 different nations, resulting in an annual death toll of 50,000–59,000. There are three important elements in handling rabies disease in post exposure prophylaxis (PEP), namely wound care, administration of anti-rabies serum, and anti-rabies vaccine.

Post-exposure prophylaxis (PEP) for rabies is widely administered and highly effective. Nevertheless, sporadic breakthrough infections (ie, rabies in people who have started PEP) have been reported. We conducted a systematic review of articles published between Jan 1, 1980 and June 1, 2022 to characterise breakthrough infections. After reviewing 3380 articles from across all continents, we identified 52 articles, which included a total of 122 breakthrough infections. We classified breakthrough infections on the basis of adherence to core practices (ie, wound cleaning and vaccine administration). Of 86 breakthrough infections with data, median time from exposure to symptom onset was 20 days (IQR 16-24). Most (89 [77%] of 115) participants received PEP within 2 days of an exposure. Severe wounds (defined as those involving multiple wound sites or bites to the head, face, or neck) were common (80 [69%] of 116 [with data]). Deviations from core practices were reported in 68 (56%) of 122 cases. Other possible causes for breakthrough infections included errors in the administration of rabies immunoglobulin, delays in seeking health care, and comorbidities or immunosuppression. Cold-chain integrity assessments and potency testing of PEP biologics were only rarely assessed (8 [7%] of 122 cases), neither of which were found to be a cause of breakthrough infections. Timely and appropriate administration of PEP is crucial to prevent rabies, and although people with high-risk exposures or immunosuppression can develop rabies despite adherence to core practices, this occurrence remains exceedingly rare.

<h4>Background</h4>Rabies post-exposure prophylaxis (PEP) requires timely appropriate wound management and vaccination (including concomitant rabies immunoglobulin [RIG], depending on vaccination history and wound severity) to ensure rapid increases in rabies virus neutralizing antibody (RVNA) titers, a surrogate marker of protection. In this systematic review and meta-analysis, we assessed factors influencing the immunogenicity of rabies vaccines administered as PEP.<h4>Methods</h4>PubMed, Embase, and The Cochrane Library were systematically searched for randomized controlled trials published in English, French, Spanish, or Portuguese from January 1, 1983 to March 28, 2022 reporting the immunogenicity of rabies vaccines, specifically rabies human diploid cell vaccine (Imovax Rabies), purified Vero cell rabies vaccine (Verorab), and purified chick embryo cell rabies vaccine (RabAvert/Rabipur), as part of PEP in healthy individuals. Pooled RVNA geometric mean titers (GMTs) and seroconversion rates at Day 14 (D14) post-vaccination, determined by rapid fluorescent focus inhibition test, were estimated using random effects meta-analyses.<h4>Results</h4>We identified 1040 studies, of which 67 (9689 participants across 140 intervention groups) were included. The pooled RVNA GMT across all vaccines at D14 post-vaccination was 8.19 (95% CI: 6.73-9.98) and did not differ significantly by vaccine, administration route, or RIG use; however, there were significant interlaboratory differences. Meta-regression analysis, including titration year, demonstrated a negative association with log-transformed RVNA GMTs, equating to a 4.18% reduction (95% CI: -5.89 to -2.44) in log-transformed GMTs per year during the period assessed. Across all vaccines assessed, the pooled seroconversion rate by D14 post-vaccination was 98% (95% CI: 97-98; n = 7023; I² = 64%) and was not impacted by vaccine, administration route, RIG use, test laboratory, or titration year.<h4>Conclusions</h4>Although RVNA GMTs appear to have decreased by titration year, there was no clinically meaningful impact on immunogenicity, and the three licensed rabies vaccines assessed are expected to provide similar protection.

Rapidity and magnitude of antibody response to duck-embryo rabies vaccine administered as a pre-exposure regimen. Rabies virus appears in the central nervous system within hours after it is introduced peripherally. It has been suggested that rapidity of appearance is an important factor in providing immunity against rabies. Since pre-exposure vaccination of man against this disease is performed in high-risk occupational groups, it is important to know the time-interval between administration of vaccine and appearance of antibody. This report shows that persons who received a booster inoculation of duck-embryo rabies vaccine 6 months after a pre-exposure course of 3 sensitizing intradermal doses of the same vaccine responded rapidly with the production of demonstrable antibody. That response was not assured if the person had failed to develop demonstrable antibody after the primary series.

vous system would become involved when vaccination could be effective. Meister was administered a series of preparations of spinal cord from rabbits that had died of rabies, beginning with tissues that had been desiccated for 15 days and ending, on the thirteenth inoculation, with virulent RABV. While the concept that postexposure rabies vaccination works by preventing central nervous system involvement cannot be formally proven in humans, it has been the theoretical basis of rabies postexposure prophylaxis (PEP) for over a century. Despite improved rabies virus vaccines and the addition of rabies virus neutralizing antibodies (VNA) to the PEP protocol, successful treatment remains limited to the first days after infection. Clearly, PEP with a conventional killed RABV vaccine and VNA is unsuccessful after clinical signs of rabies have developed, which supports the likelihood that the RABV-specific immune response elicited by this type of vaccine works by preventing spread of the virus to the CNS. Most human rabies cases are in areas where dog rabies remains endemic and are a consequence of the fact that, in these areas, financial and logistical constraints in obtaining PEP outweigh the risk of developing rabies. Where dog rabies is controlled, RABV of bat origin have emerged as the leading causative agents of human rabies. Unlike the more obvious exposures to rabies virus via a wound caused by a dog or other large animal, contact with a bat that results in rabies virus infection often goes unnoticed and bat RABV are more commonly associated with human rabies cases without a recognized exposure than variants carried by terrestrial animals [ 3 , 4 ]. The in vitro growth characteristics of the silver-haired bat RABV (SHBRV), often associated with human rabies, suggest that these variants may more efficiently spread from peripheral sites of exposure than other RABV types [ 5 ]. Moreover, cases of human rabies associated with cave exploration support the likelihood that

re and infection Primarily travelers with bat, dog, or cat contact (although a wide range of mammals can transmit virus) Prevention methods Avoid animal bites and direct contact with unfamiliar animals If bitten or scratched, thoroughly wash the wound, seek immediate medical attention, and obtain appropriate post-exposure prophylaxis Rabies is a vaccine-preventable disease Diagnostic support State health department ; rabies@cdc.gov Infectious agent Rabies is a fatal, acute, progressive encephalomyelitis caused by neurotropic viruses in the family Rhabdoviridae , genus Lyssavirus . Numerous, diverse lyssaviruses are found in various mammalian species throughout the world, all of which can cause fatal human rabies. Rabies virus is by far the most common Lyssavirus infection in humans. Tens of millions of potential human exposures and tens of thousands of deaths from rabies occur each year. Transmission The normal and most successful mode of rabies virus transmission is via the bite of a rabid animal. Rabies virus is neurotropic; it gains access to the nervous system through exposed peripheral nerve synapses after inoculation, most often through bite wounds. The virus travels from its point of entry within peripheral nerves to the central nervous system (CNS), where viral replication increases exponentially. Rabies virus then migrates from the CNS back to the peripheral nervous system (PNS) into, among other innervated tissues, the salivary glands. Rabies virus secreted in saliva allows the transmission cycle to repeat. Viral shedding typically occurs just days prior to onset of clinical signs in infected animals and humans; early clinical signs in the animal can be non-specific. In the context of foreign travel, any bite or scratch exposure from a mammal that is not available for observation and is consistent with the World Health Organization's (WHO's) case definition for a suspected rabid animal should lead to rabies post-exposure prophylaxis (Box 4.15.1). Internati

Control of Neglected Tropical Diseases Skip to main content Control of Neglected Tropical Diseases We coordinate and support policies and strategies to enhance global access to interventions for the prevention, control, elimination and eradication of neglected tropical diseases, including some zoonotic diseases. ### Vaccinations and immunization Rabies Rabies is a zoonotic viral disease which infects domestic and wild animals. It is transmitted to other animals and humans through close contact with saliva from infected animals (i.e. bites, scratches, licks on broken skin and mucous membranes). Once symptoms of the disease develop, rabies is fatal to both animals and humans. Rabies differs from many other infections in that the development of clinical disease can be prevented through timely immunization even after exposure to the infecting agent. Two types of vaccines to protect against rabies in humans exist - nerve tissue and cell culture vaccines. WHO recommends replacement of nerve tissue vaccines with the more efficacious, safer vaccines developed through cell culture as soon as possible. Cell culture vaccines which are more affordable and require less vaccine have been d